STOCKS TELEGRAPH

Category: Mid Day Movers

  • vTv Therapeutics (VTVT) Stock Skyrockets Post-Equity Completion

    vTv Therapeutics (VTVT) Stock Skyrockets Post-Equity Completion

    The shares of vTv Therapeutics Inc. (NASDAQ: VTVT) have experienced a notable surge this morning. Thia marked a significant increase of 153.26% in vTv stock to reach $21.02 per share, as verified in the current session. This uptrend in VTVT stock value coincides with the finalization of a financial operation.

    VTVT Therapeutics (VTVT) has completed a private offering with Samsara BioCapital, LLC (“Samsara”), a firm specializing in life sciences investments, along with the JDRF T1D Fund. On January 29, 2024, VTVT offered 464,377 shares of its common stock at a price of $11.81 per share, based on the 45-day Volume Weighted Average Price (VWAP).

    Furthermore, the private placement offering involved the purchase of warrants equivalent to 3,853,997 shares of common stock. A total of $51 million was generated from the PIPE. Also, in conjunction with the PIPE, vTv reduced the size of its Board of Directors from nine to seven members.

    Among the reconstituted board, three members will be appointed by the new investors, including Srinivas Akkaraju, MD, PhD, who serves as the Founder and Managing General Partner at Samsara. These strategic maneuvers aim to provide impetus to vTv’s pursuit, with the allocated funds intended to facilitate the commencement of the initial Phase 3 trial for its flagship product candidate, cadisegliatin, projected to begin in the middle of 2024.

    The company is poised to attract further investments of commendable quality as it readies itself for the inaugural Phase 3 trial of cadisegliatin. The resources amassed through the PIPE are anticipated to sustain vTv’s operations until the unveiling of topline data from the pivotal Phase 3 study of cadisegliatin, representing a significant milestone for the company.

    Having monitored vTv’s progress over an extended period, Samsara possesses an intimate understanding of cadisegliatin and harbors strong conviction regarding its potential to deliver substantial benefits to individuals grappling with T1D. Samsara pledges close collaboration with the VTVT Board and its team, offering guidance to propel the continued advancement of this highly promising initiative as it progresses towards Phase 3 development.

  • Adial (ADIL) Stock Skyrockets: Patent Award Fuels Surge

    Adial (ADIL) Stock Skyrockets: Patent Award Fuels Surge

    Adial Pharmaceuticals, Incorporated (NASDAQ: ADIL) has witnessed a remarkable upsurge in its stock valuation, experiencing a noteworthy surge of 169.28% to $2.28 per share during the current session of trading. This surge can be primarily attributed to the disclosure of the grant of a novel patent to Adial within the United States.

    Adial (ADIL) officially disclosed the issuance of patent number 11,905,562 by the United States Patent and Trademark Office on February 20, 2024. This patent encompasses the Company’s principal investigational new drug, AD04, and its capacity to target the serotonin transporter gene for the prospective treatment of opioid use disorder (OUD).

    This latest patent underscores Adial’s ongoing expansion of its Intellectual Property portfolio, particularly focusing on pivotal aspects of its primary asset, AD04, which includes its distinctive capability to target the serotonin transporter gene. ADIL maintains the belief that AD04 harbors significant potential in addressing OUD and various other substance dependencies, extending beyond its initial application in alcohol use disorder.

    The company remains steadfast in its commitment to advancing AD04 towards commercialization for alcohol use disorder treatment, while eagerly anticipating progress in treating OUD and other related conditions in the future. Earlier this month, Adial secured patent notice aimed at broadening its scope concerning the amalgamation of its proprietary genetic diagnostic tool.

    This tool is designed to identify patients with specific genotypes for the purpose of genetically tailored treatment of alcohol use disorder (AUD) and substance dependencies like OUD. Following an in-depth post hoc analysis of its ONWARD Phase 3 trial outcomes, Adial successfully identified patients with specific genotypes exhibiting highly favorable responses to AD04 treatment.

    Encouraged by these promising findings, the integration of its genetic diagnostic tool with AD04 presents a customized treatment avenue for individuals grappling with AUD and OUD. By combining predictive capabilities to identify patients most likely to benefit from AD04 treatment with the established clinical efficacy of AD04 in reducing heavy drinking days among patients with specific genotypes, Adial envisions a transformative impact on the lives of millions affected by AUD and other dependencies.

    Notably, within the cohort possessing the target genotypes, the potential market for AD04 is estimated at approximately $40 billion in the U.S. alone. Adial remains dedicated to further unraveling the genetic underpinnings of addiction and is committed to delivering a personalized therapeutic approach through AD04.

  • Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

    Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

    As of the last check this current trading session, Codexis, Inc. (NASDAQ: CDXS) was observed to have surged by 30.47%, reaching $4.18. This upward trend in Codexis stock value is propelled by an announcement of a significant licensing agreement.

    Codexis (CDXS) has formalized an exclusive, worldwide licensing deal with Roche, pertaining to the Company’s freshly engineered double-stranded DNA (dsDNA) ligase designed for next-generation sequencing (NGS) library preparation, alongside the EvoT4 DNA ligase. According to the terms outlined in the agreement, Codexis stands to gain upfront payments as well as technical milestone reimbursements. Notably, this agreement supplants the prior exclusive license concerning the EvoT4 DNA ligase.

    This transaction epitomizes the ongoing dedication of Codexis to concentrate on the pivotal sectors of its enterprise, where it can wield the most significant influence in the market. Since the articulation of its prioritized strategy last July, Codexis has successfully executed numerous agreements aimed at monetizing its non-core assets in collaboration with leading entities in the market.

    The renewal of collaboration with Roche on the innovative dsDNA ligase is a source of great anticipation. As a pioneer in NGS technologies, Roche consistently introduces crucial kits to the market, ensuring the requisite sensitivity and specificity for the forthcoming wave of pioneering NGS applications. Leveraging Roche’s technical expertise and expansive commercial footprint, Codexis now possesses the means to fully exploit the potential of its dsDNA ligase.

    Engineered through Codexis’ proprietary CodeEvolver technology, this recently developed dsDNA ligase enhances the ligation efficiency of DNA fragments and adapters during NGS library preparation, devoid of any bias. This advancement is particularly advantageous for NGS workflows demanding the utmost sensitivity, even under constraints of limited starting material.

    Compared to the wild-type enzyme, the newly engineered dsDNA ligase demonstrates superior ligation efficiency within shorter reaction durations, yielding higher library outputs and complexity while exhibiting minimal substrate sequence bias.

    Additionally, the Company is scheduled to participate in the TD Cowen 44th Annual Health Care Conference, slated for March 4-6, 2024, in Boston, Massachusetts. CDXS Management is set to engage in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET.

  • Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data

    Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data

    Stock price for Viking Therapeutics, Inc. (NASDAQ: VKTX) jumped 111.23% this current session, reaching $81.28 – a promising sign. Recent favorable clinical outcomes correlate with this increase in VKTX stock price.

    Viking Therapeutics (VKTX) disclosed encouraging Phase 2 trial findings for VK2735, a medication targeting GLP-1 and GIP receptors, aiming to tackle obesity and metabolic issues. The Phase 2 VENTURE trial has effectively met its primary objective along with all secondary goals, with subjects administered VK2735 demonstrating statistically significant declines in body mass compared to those on placebo.

    Furthermore, the study indicates that VK2735 treatment is well-tolerated and safe, with most treatment-related adverse events categorized as mild or moderate. Viking intends to engage with the FDA to discuss subsequent developmental steps for VK2735 based on these findings. Patients subjected to weekly VK2735 doses exhibited statistically notable reductions in average body mass after a 13-week regimen, ranging up to 14.7% from baseline.

    These patients also displayed statistically significant declines in average body mass compared to the placebo group, reaching up to 13.1%. Significant differences relative to both baseline and placebo were evident across all dosages starting from the first week and persisting throughout the 13-week treatment period. Weight reduction exhibited a progressive trend during the study duration, with no plateau observed at the 13-week mark.

    All VK2735 dosage levels showcased statistically significant variances compared to placebo regarding the key secondary endpoint, which assessed the proportion of patients achieving at least a 10% weight reduction. Remarkably, up to 88% of patients in VK2735 treatment cohorts achieved this milestone, compared to a mere 4% for the placebo group. VK2735 demonstrated commendable safety and tolerability profiles following a 13-week regimen of once-weekly dosing.

    Discontinuation rates in the VENTURE study remained low and evenly distributed between patients treated with VK2735 and those administered placebo. In total, 23 patients (13%) discontinued treatment during the study, with 5 (14%) in the placebo cohort and 18 (13%) among VK2735-treated cohorts.

  • Janux (JANX) Witnesses Dramatic Stock Surge On Promising Clinical Advances

    Janux (JANX) Witnesses Dramatic Stock Surge On Promising Clinical Advances

    Janux Therapeutics, Inc. (NASDAQ: JANX) has experienced a notable surge in its stock value, climbing by 193.08% to reach $44.26 on the US charts. This surge is attributed to significant advancements in its clinical development endeavors. The firm is a clinical-stage biopharmaceutical organization that focuses on creating a broad range of cutting-edge immunotherapies. Janux concentrates on its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, utilizing its in-house developed technologies.

    Janux (JANX) recently released updated clinical data that showed encouraging safety and effectiveness findings for its JANX007 and JANX008 projects. In a Phase 1a clinical study for metastatic castration-resistant prostate cancer, JANX007 showed promising outcomes. Significantly, JANX007-treated individuals had RECIST responses with PSA levels declining over time, along with controllable cytokine release syndrome (CRS) episodes, mostly of mild severity.

    Similarly, JANX008 showed promising clinical efficacy and a good safety profile while being studied in a Phase 1a clinical study for late-stage solid tumors expressing high levels of the EGFR target. Noteworthy is the limited occurrence of CRS and treatment-related adverse events (TRAEs), predominantly of low severity, suggesting a promising safety profile for JANX008.

    The observed safety profiles for both JANX007 and JANX008 support ongoing dose optimization efforts, aiming to enhance therapeutic efficacy while maintaining a favorable safety profile. Janux plans to provide updates on dose expansions for both programs in the latter part of 2024.

    These developments underscore the potential of Janux’s TRACTr and TRACIr platforms in addressing unmet medical needs in cancer treatment, particularly for patients with advanced or metastatic disease. With Janux, a number of solid tumor indications that have proven difficult to treat in the past will have new treatment options for carefully targeted tumor-specific activation while limiting off-target consequences.

    The new clinical developments of Janux Therapeutics represent a major step forward in the company’s goal of creating cutting-edge immunotherapies for cancer patients. With the encouraging safety and effectiveness results of its JANX007 and JANX008 trials, Janux is well-positioned to contribute significantly to the area of oncology and maybe enhance the prognosis of patients with difficult-to-treat cancers.

  • Stock Market Success: RAPT Therapeutics Ascends Despite Trials Setback

    Stock Market Success: RAPT Therapeutics Ascends Despite Trials Setback

    RAPT Therapeutics, Inc. (NASDAQ: RAPT) is currently experiencing a notable surge in its performance on the US stock market. At the latest check during the current session, RAPT stock has demonstrated a commendable increase of 19.51%, reaching $8.21. This positive trend persists despite a regulatory setback encountered in one of its clinical trials.

    According to a press release from RAPT Therapeutics (RAPT), the FDA has verbally notified that the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma have been placed on clinical hold.

    Awaiting official word from the FDA on the clinical hold, RAPT notes that the reason for this decision is a major adverse event of liver failure that was seen in an atopic dermatitis study participant. The exact cause of this adverse event remains undetermined, although it is potentially linked to zelnecirnon.

    Consequently, administration of zelnecirnon has been ceased in both clinical trials, alongside a suspension of new participant enrollments. It is important to note that the clinical hold does not extend to RAPT’s ongoing trial of tivumecirnon (FLX475) in oncology.

    Across the three zelnecirnon trials – comprising the two Phase 2 trials and an earlier Phase 1a/1b study – approximately 350 patients have been enrolled. To date, there have been no indications of liver toxicity observed in any other trial participants, nor in nonclinical studies.

    RAPT is conducting a thorough investigation into the aforementioned case, which involves a patient with a complex medical history, including prior drug allergies, autoimmune conditions necessitating thyroid hormone replacement therapy, and the use of an herbal supplement associated with liver failure.

    Additionally, the patient reported a prior COVID-19 infection at the time of the event. Characterizing the FDA’s decision as regrettable and unforeseen, RAPT is actively striving to obtain further insights into the matter.

    Emphasizing patient safety as paramount, the company remains dedicated to collaborating with the FDA to expediently resolve the issue at hand.

  • Investor Frenzy As MoneyHero (MNY) Stock Soars Nearly 45% On Growth Prospects

    Investor Frenzy As MoneyHero (MNY) Stock Soars Nearly 45% On Growth Prospects

    MoneyHero Limited (NASDAQ: MNY) witnessed a substantial 44.83% surge in its stock price, closing the preceding session at $2.10. This remarkable upswing in MoneyHero stock on US charts was fueled by optimistic projections of substantial growth in the regional market.

    According to a preliminary, non-audited evaluation released by MoneyHero (MNY), the company expects strong revenue growth in Singapore and Hong Kong starting in January 2024—at least 60% in Singapore and 50% in Hong Kong. MoneyHero’s growth trajectory has continuously surpassed those of its competitors, hence securing its leadership position in the sector.

    MoneyHero’s strategy has proven successful, as seen by its growing revenue pool, faster growth rate, and increasing pressure on its rivals. As important centers of the Southeast Asian economy, Singapore and Hong Kong put pressure on businesses to remain flexible in order to satisfy changing client needs through innovation and first-rate customer service.

    In this regard, MoneyHero has excelled, giving users more financial control over their own funds. As of January 2024, MoneyHero, which has been operating in Singapore since 2015 and Hong Kong since 2013, served more than 2.6 million unique monthly consumers in both regions.

    The firm intends to introduce updated solutions in 2024, utilizing state-of-the-art financial technology, most notably artificial intelligence, which demonstrates its dedication to innovation. To increase the reach and efficacy of its platform, MoneyHero is also forming alliances with artists, influencers, and key opinion leaders (KOLs).

    With a focus on being the leading platform for evaluating and choosing financial solutions, MoneyHero is fortifying its top brands in Singapore and Hong Kong, including SingSaver, MoneyHero, Seedly, and Creatory.

    MoneyHero is to provide a full ecosystem that benefits both customers and financial partners. The company has a defined strategy that centers on producing new goods, improving client experiences through technical breakthroughs, and extending its financial product offerings.

    MoneyHero’s remarkable development trajectory, supported by its technology innovations and strategic initiatives, highlights the company’s dedication to providing value to partners and customers in the financial ecosystem. MoneyHero is still on track to be a profitable company in 2024 and beyond as it keeps growing both its customer base and its product line.

  • Surge Alert: CEVA Stock Sees Significant Increase After Quarterly Results

    Surge Alert: CEVA Stock Sees Significant Increase After Quarterly Results

    During Wednesday’s trading, CEVA, Inc. (NASDAQ: CEVA) observed a noticeable surge in its stock performance on US market. Showing a significant 21.40% rise, the share concluded the day at $24.51. This positive trend follows the disclosure of CEVA’s financial results.

    CEVA, Inc. (CEVA) yesterday unveiled its financial results for the final quarter of 2023, which concluded on December 31. After experiencing a 20% drop from the $30.3 million reported for the equivalent period in 2022, the total revenue for Q4 2023 stood at $24.2 million. Considering ceased activities, the net profit for Q4 2023 amounted to $3.8 million, or $0.16 per share, diluted.

    Conversely, for the same quarter in the preceding year, the net income, incorporating discontinued operations, was $1.9 million, with diluted earnings of $0.08 per share. CEVA’s fourth-quarter earnings aligned with predictions despite the challenges encountered in its served sectors.

    Through the company’s dedication to enhancing operational efficiency, profitability and earnings potential have significantly risen. Notably, its royalties business grew for the third straight quarter, going back to growing year over year. Strong results in both the consumer and industrial IoT categories as well as recoveries in the mobile industry drove this comeback.

    lthough licensing revenues fell short of projections for the quarter, CEVA remains optimistic about diverse licensing opportunities within its technology portfolio. It anticipates augmenting its product range as it forges ahead with the development of new AI-related offerings.

    Throughout the quarter, CEVA finalized seventeen IP licensing agreements spanning various end markets and applications. Notably, two of these agreements were secured with OEMs, and three represented first-time customers. These agreements encompass consumer devices, Wi-Fi 6 for industrial IoT, Bluetooth for IoT and medical-grade hearables, AI for automotive ADAS, and 5G RedCap and cellular IoT modems, among others.

    CEVA’s position as a leader in the wireless communications market continues to strengthen, with its IP facilitating the connection of over 1.2 billion smart edge IoT devices and more than 280 million smartphones in 2023 alone. Furthermore, the company expanded its product offerings during the year by introducing the NPU family for edge AI and acquiring spatial audio software from VisiSonics, further solidifying its market presence and technological prowess.

  • Exciting Growth: enGene (ENGN) Stock Up Following Equity Agreement

    Exciting Growth: enGene (ENGN) Stock Up Following Equity Agreement

    The stock of enGene Holdings Inc. (NASDAQ: ENGN) is rising on the US charts this morning. The price of enGene stock was up 77.30% during current session to $13.51 at the time of the last check. The increase in ENGN shares follows an equity transaction.

    enGene (ENGN) stated today that it has reached an agreement to sell 20 million ordinary shares at a price of $10.00 per share, which is 31% above the closing price on February 13, 2024. On February 16, 2024, the financing is anticipated to conclude, subject to standard closing requirements. Including offering-related costs, enGene projects total revenues from the private placement to reach $200 million.

    The proceeds of this financing will be used by enGene for working capital and general corporate purposes, as well as for the ongoing evaluation of expanded development opportunities for EG-70, potential new R&D programs, and the company’s genetic medicine therapeutic candidate, EG-70, which is the subject of an ongoing pivotal study for BCG-unresponsive NMIBC.

    It is anticipated that the proceeds of this loan, along with the present cash and cash equivalents, will be adequate to support the current operational plan until 2027. Additionally, enGene said that Jason Hanson will step down as Chief Executive Officer and member of the Board of Directors following the selection of a replacement, citing personal, family, and health-related reasons.

    The ENGN Board has started looking for his replacement. He will serve as a strategic advisor to the Company and the new CEO when the latter is hired. Jason will be leaving enGene in a strong position, having spearheaded the program’s development and discovery, EG-70, for which positive clinical results have been previously published and which is currently undergoing a pivotal study.

    In addition, he oversaw the conversion of enGene into a publicly traded business and assembled a strong executive team. In order to guarantee a smooth transition and prepare enGene for its possible near-term transformation into a commercial-stage genetic pharmaceuticals firm, the Board is eager to collaborate with Jason to find the ideal replacement.

  • Brera (BREA) Soars Over 100%: Strategic Moves Pay

    Brera (BREA) Soars Over 100%: Strategic Moves Pay

    Brera Holdings PLC (NASDAQ: BREA) finds itself amidst a notable ascent on the US stock exchanges today, marking a remarkable surge. At the latest check during current trading, Brera Holdings stock demonstrated a noteworthy increase of 102.94%, reaching $2.07. This upward momentum in BREA stock is intrinsically linked to a well-orchestrated strategic maneuver.

    In a recent development, Brera Holdings (BREA) expounded upon the advantages inherent in its status as a publicly-traded multi-club ownership (“MCO”) entity within the global professional football (American soccer) domain. This innovative paradigm shift democratically opens avenues for sports club ownership to fans and investors alike, transcending the conventional confines previously monopolized by affluent magnates to embrace the accessible realm of public markets.

    Through its listing on the Nasdaq exchange, Brera Holdings extends a distinctive opportunity for shareholders to partake in the lucrative sphere of the sports industry, hitherto beyond the reach of retail investors. The company’s strategic deployment of the MCO model aims at optimizing operational efficiencies and resource allocation across its diversified portfolio, while simultaneously broadening revenue streams and leveraging valuation differentials within the soccer club hierarchy, all aimed at delivering exceptional returns to investors.

    Brera’s ambitious acquisition strategy spans across various geographical locales, targeting men’s soccer clubs ranging from the venerable Brera FC in Milan, Italy, to nascent ventures in Mozambique, Mongolia, and North Macedonia. This expansive approach not only capitalizes on soccer’s universal appeal but also unlocks a plethora of revenue streams including tournament victories, player transfer fees, and sponsorship agreements.

    A cornerstone of Brera Holdings’ strategy involves the astute exploitation of inefficiencies inherent in lower-tier soccer leagues. The unique dynamics of these markets, characterized by limited competition and formidable entry barriers, present fertile grounds for yielding above-average returns. Brera’s focus lies in identifying clubs poised at the intersection of financial disparity and competitive potential, laying the groundwork for transformative success and ascension to higher leagues without substantial financial outlays.